IN2015DN00143A - - Google Patents
Info
- Publication number
- IN2015DN00143A IN2015DN00143A IN143DEN2015A IN2015DN00143A IN 2015DN00143 A IN2015DN00143 A IN 2015DN00143A IN 143DEN2015 A IN143DEN2015 A IN 143DEN2015A IN 2015DN00143 A IN2015DN00143 A IN 2015DN00143A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- family member
- disclosed
- cell death
- positive cells
- Prior art date
Links
- 230000030833 cell death Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305821.6A EP2684896A1 (en) | 2012-07-09 | 2012-07-09 | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| US201261669866P | 2012-07-10 | 2012-07-10 | |
| PCT/EP2013/064466 WO2014009358A1 (en) | 2012-07-09 | 2013-07-09 | Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00143A true IN2015DN00143A (cs) | 2015-06-12 |
Family
ID=46514282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN143DEN2015 IN2015DN00143A (cs) | 2012-07-09 | 2013-07-09 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9611327B2 (cs) |
| EP (3) | EP2684896A1 (cs) |
| JP (1) | JP6457386B2 (cs) |
| CN (1) | CN104619725B (cs) |
| BR (1) | BR112015000449B1 (cs) |
| CA (1) | CA2878790C (cs) |
| DK (1) | DK2877491T3 (cs) |
| ES (1) | ES2727486T3 (cs) |
| IL (2) | IL236651B (cs) |
| IN (1) | IN2015DN00143A (cs) |
| PL (1) | PL2877491T3 (cs) |
| PT (1) | PT2877491T (cs) |
| SG (2) | SG10201700148UA (cs) |
| SI (1) | SI2877491T1 (cs) |
| WO (1) | WO2014009358A1 (cs) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL284430B2 (en) | 2015-01-20 | 2024-04-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| EP3048116A1 (en) * | 2015-01-23 | 2016-07-27 | International-Drug-Development-Biotech | Anti-dr5 antibodies with enhanced apoptosis potency |
| RU2017129236A (ru) * | 2015-01-26 | 2019-03-07 | Макродженикс, Инк. | Мультивалентные молекулы, содержащие dr5-связывающие домены |
| EP3112381A1 (en) * | 2015-07-01 | 2017-01-04 | FONDAZIONE IRCCS Istituto Nazionale dei Tumori | Bispecific antibodies for use in cancer immunotherapy |
| IL307994A (en) | 2015-07-16 | 2023-12-01 | Inhibrx Inc | Fusion proteins that bind to DR-5 that are multivalent and multispecific and uses thereof |
| BR112018011100A2 (pt) * | 2015-12-01 | 2018-12-04 | Genmab B.V. | anticorpo, composição, construto de ácido nucleico, vetor de expressão, célula hospedeira, método para tratamento de um indivíduo que tem um câncer, kit de partes, e, uso de um anticorpo ou de uma composição. |
| CN106397594B (zh) * | 2016-10-25 | 2019-06-04 | 中国药科大学 | 一种全人源的抗人死亡受体5的激动剂单链抗体及应用 |
| SG11201903693QA (en) | 2016-11-01 | 2019-05-30 | Genmab Bv | Polypeptide variants and uses thereof |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| UA128814C2 (uk) | 2017-02-10 | 2024-10-30 | Генмаб Б.В. | Поліпептид та його застосування |
| KR101926834B1 (ko) | 2017-03-21 | 2018-12-07 | 동아에스티 주식회사 | 항-dr5 항체 및 그의 용도 |
| JP2020522543A (ja) | 2017-06-07 | 2020-07-30 | ゲンマブ ビー．ブイ． | 変異ＩｇＧ六量体に基づく治療用抗体 |
| JP2021510740A (ja) | 2018-01-24 | 2021-04-30 | ゲンマブ ビー．ブイ． | ポリペプチド変種およびそれらの用途 |
| KR20200123782A (ko) * | 2018-02-26 | 2020-10-30 | 아이쥐엠 바이오사이언스 인코포레이티드 | 암치료를 위해 화학치료제와 병용된 다중결합 항-dr5 결합분자의 용도 |
| MX2020011552A (es) | 2018-05-03 | 2020-11-24 | Genmab Bv | Combinaciones de variantes de anticuerpos y usos de las mismas. |
| WO2020136218A1 (en) * | 2018-12-26 | 2020-07-02 | Imcheck Therapeutics Sas | Btn3a binding proteins and uses thereof |
| MA55881A (fr) | 2019-05-09 | 2022-03-16 | Genmab Bv | Schémas posologiques pour une combinaison d'anticorps anti-dr5 destinés à être utilisés dans le traitement du cancer |
| EP4055046A1 (en) | 2019-11-06 | 2022-09-14 | Genmab B.V. | Antibody variant combinations and uses thereof |
| US20230293680A1 (en) | 2020-07-23 | 2023-09-21 | Genmab B.V. | A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma |
| US20250215104A1 (en) * | 2022-03-02 | 2025-07-03 | Walden Biosciences, Inc. | Novel soluble urokinase plasminogen activator receptor (supar) binding molecules and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6284236B1 (en) | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
| AU735200B2 (en) | 1996-04-01 | 2001-07-05 | Genentech Inc. | APO-2LI and APO-3 apoptosis polypeptides |
| DE69837806T3 (de) | 1997-01-28 | 2012-01-05 | Human Genome Sciences, Inc. | "death-domain"-enthaltender rezeptor 4 (dr4), ein mitglied der tnf-rezeptor superfamilie, welcher an trail (apo-2l) bindet |
| US20050233958A1 (en) | 1997-03-17 | 2005-10-20 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| EP2017341A3 (en) * | 1998-01-15 | 2009-04-08 | Genentech, Inc. | Apo-2 ligand |
| EP1049787B1 (en) | 1998-01-23 | 2004-11-24 | Vlaams Interuniversitair Instituut voor Biotechnologie | Multipurpose antibody derivatives |
| ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
| IL146491A0 (en) | 1999-06-09 | 2002-07-25 | Genentech Inc | APo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM |
| US6444640B1 (en) | 1999-09-30 | 2002-09-03 | Ludwig Institute For Cancer Research | Compositions of trail and DNA damaging drugs and uses thereof |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| GB0020442D0 (en) | 2000-08-18 | 2000-10-04 | Nokia Networks Oy | Data transmission protocol |
| US20020155109A1 (en) | 2001-04-20 | 2002-10-24 | Lynch David H. | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 |
| CN100594935C (zh) | 2001-05-25 | 2010-03-24 | 人体基因组科学有限公司 | 免疫特异性结合trail受体的抗体 |
| EP2192130A1 (en) | 2001-07-03 | 2010-06-02 | Genentech, Inc. | Human DR4 antibodies and uses thereof |
| KR20070010046A (ko) | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Ｄｒ5 항체 및 그의 용도 |
| WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| JP2008531049A (ja) | 2005-02-28 | 2008-08-14 | セントカー・インコーポレーテツド | ヘテロ二量体タンパク質結合組成物 |
| CA2644903A1 (en) | 2006-03-10 | 2007-09-20 | Macrogenics, Inc. | Identification and engineering of antibodies with variant heavy chains and methods of using same |
| KR100847010B1 (ko) * | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
| WO2009002947A2 (en) | 2007-06-22 | 2008-12-31 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
| UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
-
2012
- 2012-07-09 EP EP12305821.6A patent/EP2684896A1/en not_active Withdrawn
-
2013
- 2013-07-09 SG SG10201700148UA patent/SG10201700148UA/en unknown
- 2013-07-09 EP EP13734785.2A patent/EP2877491B1/en active Active
- 2013-07-09 EP EP19159204.7A patent/EP3575323B1/en active Active
- 2013-07-09 IN IN143DEN2015 patent/IN2015DN00143A/en unknown
- 2013-07-09 WO PCT/EP2013/064466 patent/WO2014009358A1/en active Application Filing
- 2013-07-09 ES ES13734785T patent/ES2727486T3/es active Active
- 2013-07-09 BR BR112015000449-0A patent/BR112015000449B1/pt active IP Right Grant
- 2013-07-09 SG SG11201500177PA patent/SG11201500177PA/en unknown
- 2013-07-09 CN CN201380036952.2A patent/CN104619725B/zh active Active
- 2013-07-09 JP JP2015520954A patent/JP6457386B2/ja active Active
- 2013-07-09 CA CA2878790A patent/CA2878790C/en active Active
- 2013-07-09 PT PT13734785T patent/PT2877491T/pt unknown
- 2013-07-09 PL PL13734785T patent/PL2877491T3/pl unknown
- 2013-07-09 SI SI201331443T patent/SI2877491T1/sl unknown
- 2013-07-09 US US14/413,194 patent/US9611327B2/en active Active
- 2013-07-09 DK DK13734785.2T patent/DK2877491T3/da active
-
2015
- 2015-01-11 IL IL23665115A patent/IL236651B/en active IP Right Grant
-
2017
- 2017-02-17 US US15/436,583 patent/US10647774B2/en active Active
-
2019
- 2019-09-22 IL IL269527A patent/IL269527B/en unknown
-
2020
- 2020-04-06 US US16/841,306 patent/US20200332016A1/en not_active Abandoned
-
2023
- 2023-09-06 US US18/461,910 patent/US20240141057A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1211044A1 (en) | 2016-05-13 |
| US20170260281A1 (en) | 2017-09-14 |
| CN104619725B (zh) | 2019-04-23 |
| PT2877491T (pt) | 2019-06-07 |
| CA2878790C (en) | 2023-09-26 |
| IL236651A0 (en) | 2015-02-26 |
| US10647774B2 (en) | 2020-05-12 |
| EP3575323B1 (en) | 2024-09-11 |
| BR112015000449B1 (pt) | 2022-12-20 |
| US9611327B2 (en) | 2017-04-04 |
| EP2684896A1 (en) | 2014-01-15 |
| SI2877491T1 (sl) | 2019-08-30 |
| EP2877491B1 (en) | 2019-02-27 |
| IL236651B (en) | 2019-10-31 |
| JP2015527992A (ja) | 2015-09-24 |
| WO2014009358A1 (en) | 2014-01-16 |
| US20150139997A1 (en) | 2015-05-21 |
| CA2878790A1 (en) | 2014-01-16 |
| SG10201700148UA (en) | 2017-02-27 |
| BR112015000449A2 (cs) | 2017-08-15 |
| ES2727486T3 (es) | 2019-10-16 |
| CN104619725A (zh) | 2015-05-13 |
| IL269527A (en) | 2019-11-28 |
| JP6457386B2 (ja) | 2019-01-23 |
| EP2877491A1 (en) | 2015-06-03 |
| US20240141057A1 (en) | 2024-05-02 |
| US20200332016A1 (en) | 2020-10-22 |
| IL269527B (en) | 2021-12-01 |
| PL2877491T3 (pl) | 2020-01-31 |
| DK2877491T3 (da) | 2019-06-03 |
| SG11201500177PA (en) | 2015-03-30 |
| EP3575323A1 (en) | 2019-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00143A (cs) | ||
| IL262833A (en) | Metabolically enriched cell culture | |
| IL242273B (en) | Methods and compositions for increasing regulatory t cells + 4cd | |
| GB2515195B (en) | Improved fuel cell systems and methods | |
| EP3480321B8 (en) | Massively parallel single cell analysis | |
| EP3082840A4 (en) | Methods and assays relating to circulating tumor cells | |
| IL240881A0 (en) | Expression of the t cell balance gene, preparations, materials and methods for its use | |
| EP3114716A4 (en) | Battery cells and arrangements | |
| EP2970881A4 (en) | Compositions and methods for reprogramming hematopoietic stem cell lineages | |
| EP3028328A4 (en) | Electro-synthetic or electro-energy cell with gas diffusion electrode(s) | |
| EP3083658A4 (en) | Methods and assays relating to circulating tumor cells | |
| EP3080855A4 (en) | Electrochemical cells and components thereof | |
| EP3147974A4 (en) | Battery assembly and cell pack | |
| EP3072953A4 (en) | Cell culture container and container in which cell culture has been accommodated | |
| EP3046171A4 (en) | Fuel cell and fuel cell stack | |
| GB201319966D0 (en) | Fuel cell assembly and method | |
| GB201418271D0 (en) | Fuel cell and battery | |
| EP3052104A4 (en) | Treating inflammation using llp2a-bisphosphonate conjugates and mesenchymal stem cells | |
| EP2919309A4 (en) | SEALING MEMBER FOR FUEL CELL AND SEALING BODY FOR FUEL CELL USING SAME | |
| EP3087193A4 (en) | Compositions and methods for providing active telomerase to cells in vivo | |
| EP3164127A4 (en) | Compositions and methods to improve adoptive cell therapies | |
| ZA201505170B (en) | Tablets with improved acceptance and good storage stability | |
| KR101882068B1 (ko) | 연료 전지의 작동 | |
| EP2970883B8 (en) | Enhanced placental stem cells and uses thereof | |
| GB201401981D0 (en) | Fuel cell and battery |